⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2024Open Access

Supplementary Figure S6 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

Flurina A.M. Saner Kazuaki Takahashi Timothy Budden Ahwan Pandey Dinuka Ariyaratne Tibor A. Zwimpfer Nicola S. Meagher Sián Fereday Laura Twomey Kathleen I. Pishas Therese Hoang Adelyn Bolithon Nadia Traficante Kathryn Alsop Elizabeth L. Christie Eun-Young Kang Gregg Nelson Prafull Ghatage Cheng‐Han Lee Marjorie J. Riggan Jennifer Alsop Matthias W. Beckmann Jessica Boros Alison H. Brand Angela Brooks‐Wilson Michael E. Carney Penny Coulson Madeleine Courtney‐Brooks Kara L. Cushing‐Haugen Cezary Cybulski Mona El‐Bahrawy Esther Elishaev Ramona Erber Simon A. Gayther Aleksandra Gentry‐Maharaj C. Blake Gilks Paul R. Harnett Holly R. Harris Arndt Hartmann Alexander Hein Joy Hendley Brenda Y. Hernandez Anna Jakubowska Mercedes Jimenez-Linan Michael E. Jones Scott H. Kaufmann Catherine J. Kennedy Tomasz Kluz Jennifer M. Koziak Björg Kristjansdottir Nhu D. Le Marcin Lener Jenny Lester Jan Lubiński Constantina Mateoiu Sandra Oršulić Matthias Ruebner Minouk J. Schoemaker Mitul Shah Raghwa Sharma Mark E. Sherman Yurii B. Shvetsov T. Rinda Soong Helen Steed Paniti Sukumvanich Aline Talhouk Sarah E. Taylor Robert A. Vierkant Chen Wang Martin Widschwendter Lynne R. Wilkens Stacey J. Winham Michael S. Anglesio Andrew Berchuck James D. Brenton Ian Campbell Linda S. Cook Jennifer A. Doherty Peter A. Fasching Renée T. Fortner Marc T. Goodman Jacek Gronwald David G. Huntsman Beth Y. Karlan Linda E. Kelemen Usha Menon Francesmary Modugno Paul D.P. Pharoah Joellen M. Schildkraut Karin Sundfeldt Anthony J. Swerdlow Ellen L. Goode Anna DeFazio Martin Köbel Susan J. Ramus David D.L. Bowtell Dale W. Garsed

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S6. Mutational signatures in homologous recombination deficiency and RB1 subgroups.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Saner et al. (2024) studied this question.

synapsesocial.com/papers/68e5c1f0b6db64358755996f https://doi.org/10.1158/1078-0432.26711094.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S6 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma2024
2Supplementary Figure S7 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma2024
3Supplementary Figure S7 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma2024
4Supplementary Figure S10 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma2024
5Supplementary Figure S10 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma2024

Supplementary Figure S8 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma2024
Supplementary Figure S8 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma2024
Supplementary Figure S2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma2024